Combination of hypertension and diabetes causes rapid retinal cell death

Article

The combination of diabetes and hypertension-potentiated retinal oxidative and inflammatory stress accelerates retinal cell death and acellular capillary formation.

The combination of diabetes and hypertension-potentiated retinal oxidative and inflammatory stress accelerates retinal cell death and acellular capillary formation, reveals a paper in Molecular Vision.

A team led by Dr A.B. El-Remessy, Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, Georgia, USA, compared spontaneously hypertensive rats (SHR) to the outcomes of SHR with streptozotocin-induced diabetes (SHR+D). All rats were followed for 6 or 10 weeks, with Wistar rats were used as controls.

After six week both hypertension alone and hypertension with diabetes induced a quicker retinal cell death, compared to the control rats. The increase was linked to increased activation of phosphorylated-Jun N-terminal kinase (pJNK), phosphorylated-Akt inhibition, plasma and retinal lipid peroxides and soluble intracellular adhesion molecule-1 (sICAM-1) levels.

After 10 weeks there was a similar pattern in retinal nitrotyrosine, nuclear factor kappaB p65, and tumor necrosis factor-α expression being linked to exacerbated pJNK activation and acellular capillaries formation.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.